Evidence map›Paper›PMID 31441020›Full record

ArticleInvestigational new drugs2020

Stathmin 1 is highly expressed and associated with survival outcome in malignant adrenocortical tumours.

Bárbara Dos Santos Passaia, Keli Lima, Jean Lucas Kremer, Barbara Brito da Conceição, Beatriz Marinho de Paula Mariani, Jean Carlos Lipreri da Silva, Maria Claudia Nogueira Zerbini, Maria Candida Barisson Villares Fragoso, João Agostinho Machado-Neto, Claudimara Ferini Pacicco Lotfi

Abstract read
PubMed Publisher
In one paragraph

Article in Investigational new drugs, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 2 countries.

Bárbara Dos Santos PassaiaDepartment of Anatomy, Institute of Biomedical Science, University of São Paulo, Av. Prof. Lineu Prestes, 2415, São Paulo, SP, 05508-000, Brazil.
Keli LimaDepartment of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil.
Jean Lucas KremerDepartment of Anatomy, Institute of Biomedical Science, University of São Paulo, Av. Prof. Lineu Prestes, 2415, São Paulo, SP, 05508-000, Brazil.
Barbara Brito da ConceiçãoDepartment of Anatomy, Institute of Biomedical Science, University of São Paulo, Av. Prof. Lineu Prestes, 2415, São Paulo, SP, 05508-000, Brazil.
Beatriz Marinho de Paula MarianiAdrenal Unit, Hormone and Molecular Genetic Laboratory/LIM42, Hospital of Clinics, School of Medicine, University of São Paulo, São Paulo, Brazil.
Jean Carlos Lipreri da SilvaDepartment of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil.
Maria Claudia Nogueira ZerbiniDivision of Anatomy Pathology, Laboratory of Liver Pathology/LIM14, Hospital of Clinics, School of Medicine, University of São Paulo, São Paulo, Brazil.
Maria Candida Barisson Villares FragosoAdrenal Unit, Hormone and Molecular Genetic Laboratory/LIM42, Hospital of Clinics, School of Medicine, University of São Paulo, São Paulo, Brazil.
João Agostinho Machado-NetoDepartment of Pharmacology, Institute of Biomedical Science, University of São Paulo, São Paulo, Brazil.
Claudimara Ferini Pacicco LotfiDepartment of Anatomy, Institute of Biomedical Science, University of São Paulo, Av. Prof. Lineu Prestes, 2415, São Paulo, SP, 05508-000, Brazil. clotfi@usp.br.ORCID 0000-0002-9881-7099
Universidade de São Paulo · BR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Adrenocortical carcinoma (ACC) is an aggressive endocrine cancer with few molecular predictors of malignancy and survival, especially in paediatric patients. Stathmin 1 (STMN1) regulates microtubule dynamics and has been involved in the malignant phenotype of cancer cells. Recently, it was reported that STMN1 is highly expressed in ACC patients, and STMN1 silencing reduces the clonogenicity and migration of ACC cell lines. However, the prognostic significance of STMN1 and its therapeutic potential remain undefined in ACC. In the present study, STMN1 mRNA levels were significantly higher (p < 0.05) in ACC patients, especially in an advanced stage, and correlated with BUB1B and PINK1 expression, the prognostic-related genes in ACC. In paediatric tumours, high STMN1 expression was observed in both adrenocortical carcinoma and adrenocortical adenoma patients. Among the adult malignant tumours, STMN1 level was an independent predictor of survival outcomes (overall survival: hazard ratio = 6.08, p = 0.002; disease-free survival: hazard ratio = 4.65, p < 0.0001). Paclitaxel, a microtubule-stabilizing drug, reduces the activation of STMN1 and significantly decreases cell migration and invasion in ACC cell lines and ACC cells from secondary cell culture (all p < 0.0001). In summary, STMN1 expression may be of great value to clinical and pathological findings in therapeutic trials and deserves future studies in ACC.

Indexed as

Adrenal Cortex NeoplasmsAdrenocortical CarcinomaAdultBiomarkers, TumorCell Line, TumorCell MovementChild, PreschoolDisease-Free SurvivalFemaleGene Expression Regulation, NeoplasticHumansMalePaclitaxelPrognosisRNA, MessengerStathminBiomarkers, TumorPaclitaxelRNA, MessengerStathminSTMN1 protein, humanAdrenocortical adenomaAdrenocortical carcinomaPaclitaxelStathmin 1STMN1

Identifiers

PMID31441020
OpenAlexW2969586379

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.